Altered CD28 and CD95 mRNA expression in peripheral blood mononuclear cells from elderly patients with primary non-small cell lung cancer

Chinese Medical Journal

Volumn 123, Issue 1, 2010, Pages 51-56

  Wang, Ling ^a   Pan, Xu Dong ^a   Xie, Yan ^a   Zhang, Guang Bo ^a   Jiang, Min ^a   Zheng, Li ^a   Wang, Jin Hong ^a   Shi, Jin Fang ^a   Zhang, Xue Guang ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Aged; CD28; CD95; Immunosenescence; Non small cell lung carcinoma

Indexed keywords

CD28 ANTIGEN; FAS ANTIGEN; MESSENGER RNA;

ADULT; AGED; AGING; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; HUMAN; HUMAN CELL; LOGISTIC REGRESSION ANALYSIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; T LYMPHOCYTE; TUMOR GROWTH; UPREGULATION;

AGED; ANTIGENS, CD28; ANTIGENS, CD95; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LEUKOCYTES, MONONUCLEAR; LOGISTIC MODELS; LUNG NEOPLASMS; POLYMERASE CHAIN REACTION;

EID: 74749087712     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.01.009     Document Type: Article

References (39)

1. Globerson A, Effros RB. Ageing of lymphocytes and lymphocytes in the aged. Immunol Today 2000; 21: 515-521.
2. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000; 31: 578-585.
3. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 1998; 101: 2579-2588.
4. + peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2007; 7 (3 Suppl): 947s-957s.
5. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8: 2553-2562.
6. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002; 8: 3137-3145.
7. Balducci L, Beghe C. Cancer and age in the USA. Crit Rev Oncol Hematol 2001; 37: 137-145.
8. DePinho RA. The age of cancer. Nature 2000; 408: 248-254.
9. Shimizu K, Kinouchi Shimizu N, Asai T, Tsukada H, Oku N. Enhanced experimental tumor metastasis with age in senescence-accelerated mouse. Biol Pharm Bull 2008; 31: 847-851.
10. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998.
11. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immuno 2002; 2: 227-238.
12. Effros RB. Costimulatory mechanisms in the elderly. Vaccine 2000; 18: 1661-1665.
13. Pinti M, Troiano L, Nasi M, Monterastelli E, Moretti L, Bellodi C, et al. Development of real time PCR assays for the quantification of Fas and FasL mRNA levels in lymphocytes: studies on centenarians. Mech Ageing Dev 2003; 124: 511-516.
14. Hoser G, Wasilewska D, Domagała-Kulawik J. Expression of Fas receptor on peripheral blood lymphocytes from patients with non-small cell lung cancer. Folia Histochem Cytobiol 2004; 42: 249-252.
15. Gruber IV, El Yousfi S, Dürr-Störzer S, Wallwiener D, Solomayer EF, Fehm T. Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Res 2008; 28: 779-784.
16. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging systerm for lung cancer. Ann Thorac Cardiovasc Surg 2009; 15: 4-9.
17. Chen SM, Li YG, Wang DM. Study on changes of heme oxygenase-1 expression in patients with coronary heart disease. Clin Cardiol 2005; 28: 197-201.
18. Bustin SA. Real-time, fluorescence-based quantitative PCR: a snapshot of current procedures and preferences. Expert Rev Mol Diagn 2005; 5: 493-498.
19. Nurieva R, Thomas S, Nguyen T, Martin-Orozco N, Wang Y, Kaja MK, et al. T-cell tolerance or function is determined by combinatorial costimulatory signals. Embo J 2006; 25: 2623-2633.
20. Sanchez-Lockhart M, Marin E, Graf B, Abe R, Harada Y, Sedwick CE, et al. Cutting edge: CD28-mediated transcriptional and posttranscriptional regulation of IL-2 expression are controlled through different signaling pathways. J Immunol 2004; 173: 7120-7124.
21. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-252.
22. Foell J, Hewes B, Mittler RS. T Cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity. Current Cancer Drug Targets 2007; 7: 55-70.
23. - T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002; 168: 5893-5899.
24. Pan XD, Wang L, Shi JF, Zhang GB, Zhang XG. Expression and clinical significance of the membrane CD28 and the serum level of soluble CD28 in elderly patients with primary non-small cell lung cancer. Chin J Geriatrics (Chin) 2009; 28: 445-448.
25. + T lymphocytes during infection with Listeria monocytogenes. J Immunol 2001; 167: 5620-5627.
26. Krinzman SJ, De Sanctis GT, Cernadas M, Mark D, Wang Y, Listman J, et al. Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model. J Clin Invest 1996; 98: 2693-2699.
27. Vallejo AN. CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev 2005; 205: 158-169.
28. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, et al. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
29. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994; 179: 1205-1214.
30. Yolcu ES, Ash S, Kaminitz A, Sagiv Y, Askenasy N, Yarkoni S. Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression. Immunol Cell Biol; 2008; 86: 650-658.
31. Osborne BA. Induction of genes during apoptosis: examples from immune system. Semin Cancer Biol 1995; 6: 27-33.
32. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, et al. The CD95 receptor: apoptosis revisited. Cell 2007; 129: 447-450.
33. Aggarwal S, Gupta S. Increased apoptosis of T cell subsets in aging humans: altered expression of Fas (CD95), Fas ligand, Bcl-2, and Bax. J Immunol 1998; 160: 1627-1637.
34. Phelouzat MA, Arbogast A, Laforge T, Quadri RA, Proust JJ. Excessive apoptosis of mature T lymphocytes is a characteristic feature of human immune senescence. Mech Ageing Dev 1996; 88: 25-38.
35. Pan XD, Wang L, Shi JF, Zhang GB, Zhang XG. The expression and clinical significance of the Fas/FasL on T cells in peripheral blood of elderly patients with primary non-small cell lung cancer. Chin J Gerontology (Chin) 2008; 28: 2010-2012.
36. Whiteside TL. Tumor-induced death of immune cells: its mechanism and consequences. Semin Cancer Biol 2002; 12: 43-50.
37. Walker LS, McLeod JD, Boulougouris G, Patel YI, Hall Nd, Sansom DM. Down-regulation of CD28 via Fas (CD95): influence of CD28 on T-cell apoptosis. Immunology 1998; 94: 41-47.
38. Hoser G, Wasilewska D, Domagała-Kulawik J. Expression of Fas receptor on peripheral blood lymphocytes from patients with non-small cell lung cancer. Folia Histochem Cytobiol 2004; 42: 249-252.
39. Dennett NS, Barcia RN, McLeod JD. Age associated decline in CD25 and CD28 expression correlate with increased susceptibility to CD95 mediated apoptosis in T cells. Exp Gerontol 2002; 37: 271-283.